Core Claim

The accumulation of mitochondrial DNA (mtDNA) heteroplasmy in tissue-resident macrophages (TRMs) — not circulating monocytes — establishes organ-specific inflammaging trajectories that diverge from and are not captured by peripheral blood-based epigenetic clocks (Horvath, GrimAge, DunedinPACE).

Rationale

Tissue-resident macrophages are long-lived, self-renewing cells that persist for decades in organs like the liver (Kupffer cells), brain (microglia), lungs (alveolar macrophages), and synovium. Unlike circulating immune cells, TRMs undergo continuous mitochondrial stress from local metabolic demands without dilution through cell division or replacement from bone marrow precursors.

As heteroplasmic mtDNA mutations accumulate in TRMs, several consequences follow:

1. Impaired oxidative phosphorylation shifts TRMs toward glycolytic metabolism, mimicking M1 polarization and promoting constitutive NLRP3 inflammasome activation via increased mitochondrial ROS and cytosolic mtDNA release.
2. cGAS-STING activation by leaked mtDNA fragments drives type I interferon signaling, creating a local inflammatory milieu independent of systemic cytokine levels.
3. Organ-specific metabolic environments (hepatic lipid exposure, synovial hypoxia, alveolar oxidative stress) create distinct selective pressures on mtDNA mutations, explaining why organs age at different rates within the same individual.

Testable Predictions

1. Single-cell mtDNA sequencing of TRMs from aged human organ donors will show higher heteroplasmy burden than matched circulating monocytes, with organ-specific mutation spectra (e.g., Complex I mutations enriched in hepatic Kupffer cells vs. Complex IV in alveolar macrophages).
2. Individuals with discordant organ aging (e.g., accelerated hepatic fibrosis but normal cardiovascular age) will show correspondingly discordant TRM heteroplasmy burdens, while peripheral epigenetic clocks fail to predict this divergence.
3. Targeted depletion of high-heteroplasmy TRMs (via clodronate liposomes or CSF1R inhibition) followed by repopulation from bone marrow precursors will reset local inflammaging markers (tissue IL-6, TNF-α, SA-β-gal staining) in aged mice, without altering systemic epigenetic age.
4. Transfer of high-heteroplasmy TRMs into young syngeneic recipients will accelerate organ-specific aging markers within 8 weeks.

Implications

If confirmed, this hypothesis suggests that (a) systemic epigenetic clocks are incomplete measures of biological aging, missing critical organ-level variation; (b) senolytic strategies should be complemented by mitochondria-targeted interventions specific to TRM populations; and (c) organ-specific aging biomarkers based on TRM heteroplasmy could guide personalized geroprotective interventions.

Intersection with Autoimmune Disease

This mechanism may be particularly relevant in rheumatic diseases where synovial TRMs drive chronic inflammation. The hypoxic synovial microenvironment in rheumatoid arthritis likely accelerates mtDNA mutation accumulation in synovial macrophages, creating a feedforward loop between autoimmune inflammation and accelerated local biological aging — potentially explaining the 5-10 year gap in cardiovascular mortality observed in RA patients beyond traditional risk factors.

Key References

• Kauppila TES et al. Cell (2017): Mammalian mtDNA mutations and aging
• Yousefzadeh MJ et al. Nature (2021): Tissue-specific aging signatures
• De Maeyer RPH & Bhatt D. Nat Rev Immunol (2023): Macrophage heterogeneity in aging
• Horvath S & Raj K. Nat Rev Genet (2018): DNA methylation-based biomarkers of aging